

Development and assessment of an improved recombinant multiepitope antigen-based immunoassay to diagnose chronic Chagas disease

Research Article

Cite this article: Peverengo LM, Garcia V, Rodeles LM, Mendicino D, Vicco M, Lagier C, Gonzalez V, Gugliotta L, Marcipar I (2018). Development and assessment of an improved recombinant multiepitope antigen-based immunoassay to diagnose chronic Chagas disease. *Parasitology* **145**, 1594–1599. <https://doi.org/10.1017/S0031182018000458>

Received: 27 December 2017
Revised: 16 February 2018
Accepted: 19 February 2018
First published online: 28 March 2018

Key words:

Chagas disease; chimera; diagnostic; multiepitope; recombinant protein; *Trypanosoma cruzi*

Author for correspondence:

Luz María Peverengo, E-mail: luzpeverengo@gmail.com

Luz María Peverengo¹, Valeria Garcia², Luz María Rodeles^{1,3}, Diego Mendicino⁴, Miguel Vicco³, Claudia Lagier⁵, Verónica Gonzalez², Luis Gugliotta² and Iván Marcipar^{1,3}

¹Laboratorio de Tecnología Inmunológica (Facultad de Bioquímica y Ciencias Biológicas-Universidad Nacional del Litoral), Santa Fe, Argentina; ²INTEC (CONICET-UNL), Santa Fe, Argentina; ³Laboratorio de Investigación en Ciencias Biomédicas (Facultad de Ciencias Médicas-Universidad Nacional del Litoral), Santa Fe, Argentina; ⁴Centro de Investigaciones sobre Endemias Nacionales (FBCB-UNL), Santa Fe, Argentina and ⁵Dpto. de Química Analítica (FBOyF-UNR), Rosario, Argentina

Abstract

The use of chimeric molecules fusing several antigenic determinants is a promising strategy for the development of low-cost, standardized and reliable kits to determine specific antibodies. In this study, we designed and assessed a novel recombinant chimera that complements the performance of our previously developed chimera, CP1 [FRA and SAPA antigens (Ags)], to diagnose chronic Chagas disease. The new chimeric protein, named CP3, is composed of MAP, TcD and TSSAII/V/VI antigenic determinants. We compared the performance of both chimeric Ags using a panel of 67 *Trypanosoma cruzi*-reactive sera and 67 non-reactive ones. The sensitivity of CP3 vs CP1 was 100 and 90.2%, and specificity was 92.5 and 100%, respectively. The mixture of CP1 + CP3 achieved 100% of sensitivity and specificity. More importantly, an additional subset of 17 sera from patients with discordant results of conventional serological methods was analysed; the CP1 + CP3 mixture allowed us to accurately classify 14 of them with respect to IIF, the usual technique used in most of the reference centres. These results show an improved performance of the CP1 + CP3 mixture in comparison with enzyme-linked immunosorbent assay and indirect haemagglutination commercial assays.

Introduction

Chagas disease is an infection caused by the parasite *Trypanosoma cruzi*. According to the estimates of WHO based on 2010 data, about 5.8 million people were infected with *T. cruzi* only in 21 Latin American countries (WHO, 2015). During the chronic phase, the infection is diagnosed by detecting specific antibodies (Abs) against *T. cruzi* antigens (Ags) in a patient's serum. Detection is accomplished via conventional screening serological methods based mostly on enzyme-linked immunosorbent assay (ELISA), indirect haemagglutination (IHA) or indirect immunofluorescence (IIF). Chronic Chagas disease (CCD) diagnosis is determined when specific Abs are detected by at least two of these methods. In cases with ambiguous or discordant results, a third assay procedure is used to confirm or discard the condition, since at least two positive results of different techniques are required (WHO, 2002). The current trend is to produce immunodiagnostic assays based on recombinant proteins as sensitizing elements to improve the diagnostic performance, achieve more standardized assays, reduce costs and avoid the use of pathogenic microorganisms (Houghton *et al.* 1999; da Silveira *et al.* 2001; Aguirre *et al.* 2006; Camussone *et al.* 2009; Praast *et al.* 2011; Granjon *et al.* 2016; Santos *et al.* 2017). However, as single Ags are often not sensitive enough, mixtures of these Ags are commonly used (WHO, 2010). In order to improve the performance of an immunoassay prepared with multiple Ags, multiepitope proteins expressing several unrelated antigenic determinants have been also proposed (Houghton *et al.* 1999, 2000; Aguirre *et al.* 2006). This strategy would offer several advantages, such as (i) a decrease in the amount of Ags used in the immunoassays, (ii) controlled proportion of antigenic determinants that are displayed to Abs, (iii) increased number of epitopes available on the same surface, (iv) simpler production processes (da Silveira *et al.* 2001; Marcipar and Lagier, 2012).

Several chimeric Ags have been described to be used for the diagnosis of CCD (da Silveira *et al.* 2001; Marcipar and Lagier, 2012). These previously reported chimeras were composed mainly of different combinations of FRA, CRA, SAPA, TcD, MAP, B13, TcE, Tc29 *T. cruzi* Ags. In the present work, a novel chimeric multiepitope construct (CP3) was synthesized. Highly conserved antigenic sequences (MAP and TcD), which have shown to be useful when incorporated in chimeras, were fused with mucin-like glycoprotein (TSSAII/V/VI). This antigenic determinant is displayed on the surface of infective trypomastigote forms of

parasite lineages II, V and VI (Di Noia *et al.* 2002). This Ag has been assessed individually, in mixtures or in an array with other proteins to diagnose CCD, and has been found to be a promising candidate; to date, however, it has not been used in chimeras (De Marchi *et al.* 2011; Balouz *et al.* 2015; Granjon *et al.* 2016).

In a previous work, we reported that, among different recombinant Ags candidates, the multiepitope Ag CP1 carrying FRA and SAPA was the most promising one (Camussone *et al.* 2009). In the present study, we aimed to assess the diagnostic performance of the new Ag CP3 to detect *T. cruzi* chronic infection by developing an indirect ELISA and determining if it could enhance discrimination ability of CP1 protein.

Materials and methods

Production and purification of antigenic recombinant protein

The CP3 gene was synthesized by Integrated DNA Technologies (IDT, Coralville, Iowa, USA). The synthetic gene, with 375 base pairs, encodes three *T. cruzi*-specific antigenic proteins: MAP, TcD and TSSA. The gene was subcloned into the EcoRI/SacI sites of pET-28a (Novagen, Madison, WI, USA); the resulting plasmid was named pET28a/CP3. The CP1 clone, previously described by our group (Camussone *et al.* 2009), was subcloned in pET28a into the EcoRI/SacI sites of pET-28a (Novagen, Madison, WI, USA); the resulting plasmid was named pET28a/CP1.

Expression and purification

BL21 (DE3) competent *Escherichia coli* cells were transformed with pET28a/CP3 and pET28a/CP1 plasmids by thermal shock at 42 °C for 45 s. The bacteria expressing different proteins were cultured in Luria-Bertani medium supplemented with kanamycin. Cells were grown overnight at 37 °C under agitation until OD₅₀₀ ~0.5–0.6 and induced at room temperature with 0.1 mM IPTG during 16 h. Cells were harvested by centrifugation at 5000 rpm for 5 min. After that, they were resuspended in distilled water and disrupted by sonication on ice (Vibre-Cell, Sonic & Material Inc) until culture clarification. The suspension was centrifuged at 10 000 rpm for 5 min and four volumes of the supernatant (crude extract) were supplemented with one volume of 5× phosphate buffer-imidazole 20 mM, pH = 7.4. The solution was loaded on a previously equilibrated HisTrap 1 mL column (Ni-NTA Agarose R901-15, Invitrogen). The recombinant protein was eluted with a linear gradient from 20 to 500 mM imidazole. The bicinchoninic acid assay (BCA) was performed for protein quantification and the absorbance was read at 562 nm (Bainor *et al.* 2011). The purity of the recombinant proteins was analysed using 15% sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and staining with Coomassie brilliant blue, according to the method described by Laemmli (1970).

Protein antigenicity evaluation

Serum panel

Serum samples from chronic *T. cruzi*-infected patients ($n = 67$) were obtained from blood donors attending the J. B. Iturraspe Hospital (Santa Fe, Argentina). Two different commercial tests including ELISA (Chagatest ELISA) and IHA (Chagatest IHA) from Wiener Lab (Argentina) were employed to assess the chronic infection status. The serological condition was confirmed as positive when concordant results were obtained, as established by standard technical procedures by the WHO (2002). According to the information provided by subjects, none of them had previously received specific anti-*T. cruzi* treatment.

Serum samples from *T. cruzi*-non-infected patients ($n = 67$) were obtained also from blood donors from the same hospital.

Those samples also rendered negative results for syphilis, human immunodeficiency virus and hepatitis A, B and C. According to the last practice guideline of the National Health Institute regarding the management of biospecimen resources, informed consent obtained from blood donors is not mandatory, while the anonymous use of these samples is ensured. Nevertheless, at the moment of the blood collection, the usual institutional form filled by the patients includes a section where non-identifiable use of the remanent serum is authorized for research (National Institutes of Health, 2016).

An additional subset of 17 discordant samples was obtained from patients that were previously examined by IHA (Chagatest HAI, Wiener Lab, Argentina) and ELISA (Chagatest ELISA recombinant 4.0, Wiener Lab, Argentina) and that exhibited discordant results even after both methods were repeated at least twice. In these cases, written consent was obtained after patients had been fully informed about the study. The serological status of these patients was defined by IIF performed in a reference centre (Central Laboratory of the Santa Fe Province). In all serum samples included, the result given by the third reaction was in accordance with clinical and epidemiological information of the patient obtained by a physician at the same centre, especially regarding cardiac and digestive manifestations of the disease.

The original study protocol was approved by the Ethics Review Board of the Santa Fe Province (RP N° 300). The procedures followed the ethical standards given in the 1964 Declaration of Helsinki and its later amendments.

Enzyme-linked immunosorbent assay

Ninety-six-well ELISA microplates were coated with the Ags or the mixture, respectively, at 37 °C for 1 h and then at 4 °C overnight. The optimal amount of Ag per well was preliminary determined by checkerboard titration with reactive and non-reactive sera: 100 ng per well for CP3, 100 ng per well for CP1 and 100:100 ng per well of CP1 and CP3, in carbonate-bicarbonate buffer (pH 9.6). The next day, microplates were washed several times with phosphate-buffered saline (PBS) containing 0.05% (v/v) Tween 20, blocked with 5% skimmed milk/PBS for 30 min at 37 °C, and incubated with a 1:100 dilution of human serum in 1% skimmed milk in PBS for 30 min at 37 °C. Bound Abs were assayed by incubating (37 °C for 30 min) with peroxidase-conjugated goat anti-human immunoglobulin G (Jackson) and diluted 1:26.000 in 1% skimmed milk in PBS. Between each step, the plates were washed four times with PBS containing 0.05% (v/v) Tween 20. The enzyme reaction was developed with 100 µL per well of tetramethyl benzidine (Zymed) in H₂O₂. The reaction was stopped using 100 µL per well of 0.5 N H₂SO₄ and plates were read at 450 nm on ELISA reader (Molecular Devices Emax).

Data analysis

All serum samples were evaluated in duplicate, with the result of the test being the mean optical density (OD) value of these simultaneous determinations. ELISA *cut-off* values were calculated as the mean OD of the true-negative serum samples plus 2 standard deviations of that mean. ELISA results were then expressed as an index of optical density (IOD) of the sample in relation to *cut-off*; an IOD <1 was considered negative. Grey zone was calculated as ± 10% of the *cut-off* (0.9–1.10 IOD) (WHO, 2010).

IOD medians for positive samples were compared among the three different Ags conditions by Kruskal–Wallis test and Dunn's multiple comparison post-test analysis. IOD values of samples were distributed using scatter computer graphic software (GraphPad Prism version 5.03). The diagnostic test was evaluated using receiver operating characteristic (ROC) curve analysis by calculating sensitivity, specificity and area under the curve (AUC).




Fig. 2. Assessment of CP1 and CP3 chimeras as single Ags to diagnose CCD. (A) Relative IOD of specific Abs distribution for the studied Ags (CP1 and CP3) on a panel composed of 67 *Trypanosoma cruzi*-positive and 67 *T. cruzi*-negative patients. The central tendency line shows the relative median (IQR) values for reactive sera for each assay, and the dashed line indicates the relative *cut-off* value (IOD/*cut-off* = 1). The grey zone is presented as a continuous line in this colour. (B) Dot plot of log₂ of IOD values of Abs detected by CP3 in x-axis and CP1 in y-axis showing the complementarity of both Ags. The dashed line indicates the relative *cut-off* value (IOD/*cut-off* = 1). The grey zone is presented as a continuous line in this colour. (C and D) ROC curves obtained for IOD of Abs detected with CP1 and CP3 proteins on the serum panel.




Fig. 3. Assessment of the mixture CP1+CP3 to diagnose CCD. (A) Relative IOD distribution of Abs obtained from a panel of 67 Chagas disease-positive and 67 negative serum samples for the CP1+CP3 mixture. The continuous lines show the relative median values of reactive and non-reactive sera, respectively, in the assay, and the dashed line indicates the relative *cut-off* value (IOD/*cut-off* = 1). The grey zone is presented as a continuous line in this colour. (B) ROC curves obtained for the CP1+CP3 mixture on the serum panel.

knowledge, it has never been incorporated into a chimera. Interestingly, this Ag has been originally described as a candidate to typify the lineage of infecting parasite using the Abs from infected persons (Di Noia *et al.* 2002). Therefore, Abs against this Ag in infected patients would be detected only in individuals with these lineages. However, these lineages are highly prevalent in South America (Burgos *et al.* 2010). Accordingly, several works have reported appropriate diagnostic performance when used as a single Ag (Bhattacharyya *et al.* 2010; Cimino *et al.* 2011; De Marchi *et al.* 2011). Based on these previous reports, we have supplemented the Ags FRA, SAPA, MAP and TcD with TSSA II/V/VI. The novel chimeric Ag was able to be expressed and purified in soluble form, a characteristic that makes it suitable for use in an ELISA assay. Although CP1 and CP3 had similar performances based on ROC analysis, we found that sera rendering negative results with CP1 protein were properly classified using CP3. The number of sera that renders results in the grey zone was also notably decreased when the results of CP1 and CP3 were integrated.

Based on this finding highlighting the complementarity of these proteins, we inferred that antigenic determinants from CP1 mixed with those present in the CP3 would be useful to correctly define the chronic infection of *T. cruzi* in humans. To assess this possibility, we used the mixture of CP1 and CP3 in a single well to determine if it improved the discrimination between the OD of reactive and non-reactive sera in relation to the use of the respective single Ag. This CP1 + CP3 mixture successfully classified all reactive and non-reactive sera of the complete panel. It should be noted that samples that could not be correctly classified as positive using CP1 rendered positive values with the use of the mixture. This could indicate that the epitopes from CP1 and CP3 molecules that improve the diagnostic performance in relation to the use of single Ags were correctly displayed on the surface of ELISA well.

In turn, negative sera that were misclassified as positive by CP3 were negative by using the mixture CP1 + CP3 which may be explained by a favourable change in the IOD value distribution to discriminate positive from negative samples. In fact, the median IOD value of positive sera increased with the use of combined Ags as compared with the use of single proteins, indicating complementarity and synergy between these Ags.

Considering the phylogenetic proximity between *T. cruzi* and *Leishmania*, the usefulness of these Ags should be evaluated using sera from patients with *Leishmania* and without Chagas disease to determine possible cross-reactions. In a previous work, we assessed CP1 Ag using Abs from *Leishmania* spp.-infected individuals and non-cross-reactivity was detected in these sera (Camussone *et al.* 2009). Furthermore, TSSA II/V/VI displayed no cross-reactivity with Abs from *Leishmania* spp.-infected individuals (De Marchi *et al.* 2011). We plan to complete CP1 + CP3 assessment using a panel of *Leishmania*-infected patients. However, considering that in Argentina both infections tend to co-exist in endemic regions and that currently available techniques do not ensure the absence of *T. cruzi* infection, careful selection of patients is necessary.

Chagas disease is currently diagnosed using two different serological reactions, as established by standard technical procedures and acknowledged by the World Health Organization (WHO, 2002; Ministerio de Salud de la Nación Argentina, 2012). When discordant results are obtained, a third assay must be performed using a high sensitivity test, such as ELISA or IIF (Ministerio de Salud de la Nación Argentina, 2012). These instructions indicated by health authorities are important to obtain reliable results; however, they usually produce an important proportion of discordant results; 3.3% of discordant results were recently reported in a study of 4939 individuals screened in Europe (Moure *et al.*

2016). Adequate selection of Ags could reduce these discordances, reducing time and costs of the diagnosis. To assess the capacity of our CP1 + CP3 mixture to correctly characterize samples, we used a serum panel from those cases that had produced discrepant IHA and ELISA results when evaluated with the commercial kits. In all serum samples used in this study, the result given by the third reaction (IIF) was in accordance with the clinical and epidemiological data previously obtained from patient characterization. Although in some cases the patient clinical features may not be specific for Chagas disease, this information is complementary and supports the analytical classification of the included samples. This fact is considerably relevant, because there is still no gold standard technique defined by a scientific committee to contrast new trials, and it is quite difficult to obtain samples with such a complete set of data.

Of this seventeen discordant serum panel, only three samples displayed false-positive results using the CP1 + CP3 mixture. This result indicates a better performance of the CP1 + CP3 mixture than the ones displayed by the commercial IHA and ELISA tests, such as ELISA recombinante V.4, which is composed of a mixture of SAPA, Ag1 (FRA), Ag 30 (CRA), Ag 2 (B13), Ag13 (TcD) and Ag36 (MAP). In a previous work (Camussone *et al.* 2009), we determined that both CRA and B13, which are not present in our current chimeras but are used in the commercial assay, tend to display high reactivity with sera from uninfected patients. The absence of these Ags in CP1 and CP3 chimeras and the incorporation of TSSA II/V/VI Ag in CP3 to increase the sensitivity would, therefore, be responsible for our favourable results. Accordingly, CP1 + CP3 is a quite promising mixture to accurately diagnose chronic *T. cruzi* infection. This candidate for CCD diagnosis should be further validated in a larger serum panel including samples from patients infected only with *Leishmania*.

Acknowledgements. We are grateful to Marcelo Nepote for helping in sample logistics, to Hospital J. B. Iturraspe (Santa Fe, Argentina) for providing characterized serum samples.

Financial support. The authors wish to thank CONICET, UNL and UNR for financial support.

Conflict of interests. None.

References

- Aguirre S, Silber AM, Brito MEF, Ribone ME, Lagier CM and Marcipar IS (2006) Design, construction, and evaluation of a specific chimeric antigen to diagnose Chagasic infection. *Journal of Clinical Microbiology* **44**, 3768–3774.
- Bainor A, Chang L, McQuade TJ, Webb B and Gestwicki JE (2011) Bicinchoninic acid (BCA) assay in low volume. *Analytical Biochemistry* **410**, 310–312.
- Balouz V, Cámara MdLM, Cánepa GE, Carmona SJ, Volcovich R, Gonzalez N, Altchek J, Agüero F and Buscaglia CA (2015) Mapping antigenic motifs in the trypomastigote small surface antigen from *Trypanosoma cruzi*. *Clinical and Vaccine Immunology: CVI* **22**, 304–312.
- Bhattacharyya T, Brooks J, Yeo M, Carrasco HJ, Lewis MD, Llewellyn MS and Miles MA (2010) Analysis of molecular diversity of the *Trypanosoma cruzi* trypomastigote small surface antigen reveals novel epitopes, evidence of positive selection and potential implications for lineage-specific serology. *International Journal for Parasitology* **40**, 921–928.
- Burgos JM, Diez M, Vigliano C, Bisio M, Risso M, Duffy T, Cura C, Brusses B, Favalaro L, Leguizamon MS, Lucero RH, Laguens R, Levin MJ, Favalaro R and Schijman AG (2010) Molecular identification of *Trypanosoma cruzi* discrete typing units in end-stage chronic Chagas heart disease and reactivation after heart transplantation. *Clinical Infectious Diseases* **51**, 485–495.
- Camussone C, Gonzalez V, Belluzo MS, Pujato N, Ribone ME, Lagier CM and Marcipar IS (2009) Comparison of recombinant *Trypanosoma cruzi*

- peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis. *Clinical and Vaccine Immunology: CVI* **16**, 899–905.
- Carvalho MR, Krieger MA, Almeida E, Oelemann W, Shikanai-Yassuda MA, Ferreira AW, Pereira JB, Sáez-Alquézar A, Dorlhiac-Llacer PE and Chamone DF** (1993) Chagas' disease diagnosis: evaluation of several tests in blood bank screening. *Transfusion* **33**, 830–834.
- Cimino RO, Rumi MM, Ragone P, Lauthier J, Alberti D' Amato A, Quiroga IRL, Gil JF, Cajal SP, Acosta N, Juárez M, Krolewiecki A, Orellana V, Zacca R, Marcipar I, Diosque P and Nasser JR** (2011) Immuno-enzymatic evaluation of the recombinant TSSA-II protein of *Trypanosoma cruzi* in dogs and human sera: a tool for epidemiological studies. *Parasitology* **138**, 995–1002.
- da Silveira JF, Umezawa ES and Luquetti AO** (2001) Chagas disease: recombinant *Trypanosoma cruzi* antigens for serological diagnosis. *Trends in Parasitology* **17**, 286–291.
- De Marchi CR, Di Noia JM, Frasc ACC, Amato Neto V, Almeida IC and Buscaglia CA** (2011) Evaluation of a recombinant *Trypanosoma cruzi* mucin-like antigen for serodiagnosis of Chagas' disease. *Clinical and Vaccine Immunology: CVI* **18**, 1850–1855.
- Di Noia JM, Buscaglia CA, De Marchi CR, Almeida IC and Frasc ACC** (2002) A *Trypanosoma cruzi* small surface molecule provides the first immunological evidence that Chagas' disease is due to a single parasite lineage. *The Journal of Experimental Medicine* **195**, 401–413.
- Granjon E, Dichtel-Danjoy M-L, Saba E, Sabino E, Campos de Oliveira L and Zrein M** (2016) Development of a novel multiplex immunoassay multi-cruzi for the serological confirmation of Chagas disease. *PLoS Neglected Tropical Diseases* **10**, e0004596.
- Houghton RL, Benson DR, Reynolds LD, McNeill PD, Sleath PR, Lodes MJ, Skeiky YAW, Leiby DA, Badaro R and Reed SG** (1999) A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to *Trypanosoma cruzi* in radioimmunoprecipitation-confirmed and consensus-positive sera. *The Journal of Infectious Diseases* **179**, 1226–1234.
- Houghton RL, Benson DR, Reynolds L, McNeill P, Sleath P, Lodes M, Skeiky YAW, Badaro R, Krettli AU and Reed SG** (2000) Multiepitope synthetic peptide and recombinant protein for the detection of antibodies to *Trypanosoma cruzi* in patients with treated or untreated Chagas' disease. *The Journal of Infectious Diseases* **181**, 325–330.
- Laemmli UK** (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680–685.
- Marcipar IS and Lagier CM** (2012) Advances in serological diagnosis of Chagas' disease by using recombinant proteins. In Alfonso J. Rodriguez-Morales (ed.), *Current Topics in Tropical Medicine*. Rijeka, Croatia: InTech, pp. 273–298. doi: 10.5772/28100.
- Ministerio de Salud de la Nación Argentina** (2012) Guías para la atención al paciente infectado con *Trypanosoma cruzi* (Enfermedad de Chagas). Available online at http://www.msal.gov.ar/chagas/images/stories/Equipos/Guia_Nacional_Chagas_version_27092012.pdf
- Moure Z, Angheben A, Molina I, Gobbi F, Espasa M, Anselmi M, Salvador F, Tais S, Sánchez-Montalvá A, Pumarola T, Albajar-Viñas P and Sulleiro E** (2016) Serodiscordance in chronic Chagas disease diagnosis: a real problem in non-endemic countries. *Clinical Microbiology and Infection* **22**, 788–792.
- National Institutes of Health** (2016) *NCI Best Practices for Biospecimen Resources*. Available online at <https://biospecimens.cancer.gov/bestpractices/2016-NCIBestPractices.pdf>
- Oelemann WM, Vanderborght BO, Verissimo Da Costa GC, Teixeira MG, Borges-Pereira J, De Castro JA, Coura JR, Stoops E, Hulstaert F, Zrein M and Peralta JM** (1999) A recombinant peptide antigen line immunoassay optimized for the confirmation of Chagas' disease. *Transfusion* **39**, 711–717.
- Praast G, Herzogenrath J, Bernhardt S, Christ H and Sickinger E** (2011) Evaluation of the Abbott ARCHITECT Chagas prototype assay. *Diagnostic Microbiology and Infectious Disease* **69**, 74–81.
- Santos FLN, Celedon PAF, Zanchin NIT, Souza WV, de Silva ED, da Foti L, Krieger MA and Gomes YdM** (2017) Accuracy of chimeric proteins in the serological diagnosis of chronic Chagas disease – a phase II study. *PLoS Neglected Tropical Diseases* **11**, e0005433.
- Umezawa ES, Bastos SF, Coura JR, Levin MJ, Gonzalez A, Rangel-Aldao R, Zingales B, Luquetti AO and da Silveira JF** (2003) An improved serodiagnostic test for Chagas' disease employing a mixture of *Trypanosoma cruzi* recombinant antigens. *Transfusion* **43**, 91–97.
- World Health Organization** (2002) Control of Chagas disease: second report of the WHO expert committee. Geneva: WHO.
- World Health Organization** (2010) Report 1. Anti-*Trypanosoma cruzi* Assays Operational Characteristics. Geneva: WHO.
- World Health Organization** (2015) Weekly epidemiological record Relevé épidémiologique hebdomadaire. Geneva: WHO.